• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Generex Biotechnology Has Strong Presence at Annual Canadian Diabetes Association Conference

Posted on: Thursday, 19 October 2006, 12:00 CDT

Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will make a podium presentation today at the 2006 Canadian Diabetes Association (CDA) Professional Conference and Annual Meetings in Toronto, Canada. The presentation, to be made by Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs, relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and is of a paper entitled 3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin. The paper was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre and Jeannette Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador.

In addition, the following Generex-sponsored studies are the subject of poster presentations at the CDA Professional Conference: The first poster, entitled Generex Metformin Gum: An Alternative Method for Delivery of Biguanides, was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, the Company's Vice-President - Medical Affairs. The second poster, entitled Ii-Key/Insulin MHC Class-II Antigenic Epitope Peptides in Type 1 Diabetes was authored by Professor Paolo Pozzilli and Dr. Marta Vadacca, both of the Department of Endocrinology and Diabetes at University Campus Bio-Medico, together with Robert E. Humphreys, Nikoletta L. Kallinteris, Luciana Valente, and Giuditta Valorani.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects,""plans,""intends,""believes,""will,""estimates,""forecasts,""projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

 Contacts: Shayne Gilliatt Generex Biotechnology Corporation Phone: (800) 391-6755 or (416) 364-2551  Andrew Hellman CEOcast, Inc. Phone: (212) 732-4300  Dolores Naney Rubenstein Public Relations Phone: (212) 843-8018  

SOURCE: Generex Biotechnology

Source: MARKET WIRE

More News in this Category